<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microsatellite instability (MSI) is the molecular fingerprint of the deficient mismatch repair (MMR) system, which characterizes âˆ¼15% of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>MSI develops as a result of germline mutations in MMR genes or, more commonly, from epigenetic silencing of MLH1 in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> occurring in a background of methylation of CpG islands in gene promoter regions and in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that frequently show hotspot mutations in the BRAF oncogene </plain></SENT>
<SENT sid="2" pm="."><plain>MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> have distinct phenotypic features and have been consistently associated with a better stage-adjusted prognosis compared with microsatellite stable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MSI negatively predicts response to <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> and may also determine responsiveness to other drugs used for treatment of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Recent data have expanded the molecular <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and may contribute to our understanding of differential chemosensitivity </plain></SENT>
<SENT sid="5" pm="."><plain>The ability to identify deficient MMR has important implications for patient management, and it holds promise for therapeutic exploitation and for the development of novel therapeutics </plain></SENT>
</text></document>